PCI – 7th June 2024
Thermofisher: Thu 29 February 2024, 11:15

Current Edition

Upcoming Events

NexGen Biomed 23.01.25
PFS & Injectable drug devices west coast
PFS & Injectable Drug Devices East Cost
AI in Drug Discovery
Bio Trinity
Anglo Nordic

Advertisement

A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault – 18.03.2025
Biopharma Group – 19th March 2025
Light Cast – 17.07.2025
QMB Innovation Centre

Almac Pharma Services Opens Doors on £65m New Commercial Manufacturing Facility 

Centre of Excellence is a timely response to emerging pipeline needs in highly potent drug development 

Almac Group has today announced the official opening of a new, state-of-the-art, £65m commercial manufacturing facility for Almac Pharma Services at its global headquarters in Craigavon, Northern Ireland.  

The new 100,000sq ft facility enhances existing capabilities in commercial manufacture of oral dose treatments for a variety of therapeutic areas. The high-specification production suites, managed by Almac Pharma Services’ experienced scientific and operational teams, are fully equipped with the latest in pharmaceutical manufacturing technology and includes an extension to current production scales of potent and highly potent drug products.

Construction of the building was completed in late 2024 and following successful completion of validation activities, manufacture of GMP batches will commence next week (18th March) in the regulatory approved facility. This Centre of Excellence has been designed with flexibility and a wide range of uses in mind and includes opportunities for partner companies to install custom and / or dedicated technology tailored to their individual and emerging pipeline needs. 

“We are thrilled to officially open our new commercial manufacturing facility at our global headquarters site,” John McQuaid, President and Managing Director, Almac Pharma Services. “This investment underscores our commitment to supporting our clients’ growing needs with the highest level of service and expertise.   

“The new facility not only expands our range of capabilities but also reinforces our position as an industry leader in pharmaceutical development and commercial manufacturing with an ability to tailor our services to suit individual products. It also demonstrates our commitment to working in true partnership with our clients as we support them in bringing important new therapies to the patients we serve.” 

This £65 million investment by Almac Pharma Services in Craigavon marks a significant milestone in Almac Group’s ongoing global expansion programme. Almac initially committed to £250 million in capital investment and a growth of 1,800 new jobs across the Group globally in 2022.  Since then, the Group has increased its projected investment figure to over £400 million.

The Bridge 28.01
Newcells 3 June 2024, 15:12
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
Asychem – 10.04.2025
Taconic Biosciences – 29.04.25
Steribar – 12.05.2025
Crown Bioscience 08.09.2025
Polypure hompage